nach oben

World Journal of Urology

Erschienen in:

01.05.2015 | Original Article

Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH

verfasst von: Nadir I. Osman, Christopher R. Chapple, Teuvo L. Tammela, Andreas Eisenhardt, Matthias Oelke

Erschienen in: World Journal of Urology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the long-term safety (primary objective) and efficacy/impact on quality of life (QoL, secondary objectives) of silodosin 8 mg once daily in men with LUTS/BPH.

Patients and Methods

Men who completed the 12-week double-blind study with silodosin 8 mg, tamsulosin 0.4 mg, or placebo were offered to continue with the 9-month open-label study during which all patients received silodosin 8 mg once daily. Safety was assessed by analysing vital signs, electrocardiograms, laboratory tests, and adverse events. Efficacy was evaluated with the International Prostate Symptom Score (IPSS), IPSS voiding and storage sub-scores, IPSS–QoL, and maximum urinary flow rate (Q _max).

Results

A total of 500 patients (mean age 66 years) entered the 9-month open-label study. Treatment-emergent adverse events (TEAE) were experienced by 33.4 % patients. Ejaculation dysfunction was the most common TEAE (9.0 %) but led to study discontinuations in only 1.6 % of patients. Dizziness without orthostatic hypotension occurred in 0.8 %. A marked reduction in total IPSS (−2.7 ± 3.8) was documented at the first visit of this extension phase in patients having de novo silodosin compared with lesser improvement in patients previously treated with silodosin (−0.82 ± 4.2) or tamsulosin (−0.83 ± 3.8). Improvements were maintained throughout the open-label phase. QoL also improved, with the greatest improvement in de novo silodosin patients. No relevant changes in Q _max occurred.

Conclusions

Long-term treatment with silodosin was safe and efficacious. Abnormal ejaculation was the most common TEAE, but led to treatment discontinuation in only 1.6 % of patients. Orthostatic hypotension was not seen, and only a few patients experienced dizziness.

Kupelian V, Wei JT, O’Leary MP, Kusek JW, Litman HJ, Link CL, McKinlay JB, BACH survey investigators (2006) Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Int Med 166:2381–2387CrossRef

Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479PubMed

Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, Aiyer LP, Tubaro A, Chapple CR, Wein AJ, EpiLUTS Team (2009) The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA UK and Sweden: EpiLUTS. BJU Int 103(Suppl 3):12–23CrossRefPubMed

van Koeveringe GA, Vahabi B, Andersson KE, Kirschner-Hermanns R, Oelke M (2011) Detrusor underactivity: a plea for new approaches to a common bladder dysfunction. Neurourol Urodyn 30:723–728CrossRefPubMed

Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K (2008) Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 54:419–426CrossRefPubMed

Chapple CR, Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49:651–658CrossRefPubMed

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette J, European Association of Urology (2013) EAU Guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms, including benign prostatic obstruction. Eur Urol 64:118–140CrossRefPubMed

Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94:738–744CrossRefPubMed

Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148:1467–1474PubMed

10.

Chapple CR, Carter P, Christmas TJ et al (1994) A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74:50–56CrossRefPubMed

11.

Fine SR, Ginsberg P (2008) Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. J Am Osteopath Assoc 108:333–337PubMed

12.

Lowe FC (2004) Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26:1701–1713CrossRefPubMed

13.

Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG (2003) Use of alpha-blockers and the risk of hip/femur fractures. J Intern Med 254:548–554CrossRefPubMed

14.

Thorpe A, Neal D (2003) Benign prostatic hyperplasia. Lancet 361:1359–1367CrossRefPubMed

15.

Michel MC, Grübbel B, Möllhoff S et al (1994) 1-Adrenoceptor affinities of drugs for the treatment of benign prostatic hyperplasia in human prostate, rat tissues and at cloned subtypes. Abstract presented at: 23rd Congress of the Société Internationale d’Urologie; September 18–24, Sydney, Australia. Abstract 649

16.

Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M (1994) Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113:723–728CrossRefPubMedCentralPubMed

17.

Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N (2006) Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 126:209–216CrossRefPubMed

18.

Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez EF, European Silodosin Study Group (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59:342–352CrossRefPubMed

19.

Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group (2006) Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019–1024CrossRefPubMed

20.

Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G (2009) Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181:2634–2640CrossRefPubMed

21.

Miller J, Carson CC (2007) Alpha blockers and ejaculatory function: a state of the art review. Curr Sex Health Rep. 4:141–144CrossRef

22.

Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F (2012) Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother 13:2085–2096CrossRefPubMed

23.

Montorsi F, Mercadante D (2013) Diagnosis of BPH and treatment of LUTS among GPs: a European survey. Int J Clin Pract 67:114–119CrossRefPubMed

24.

Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G (2009) Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 74:1318–1322CrossRefPubMed

25.

van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of α1-adrenoceptor antagonists on male sexual function. Drugs 66:287–301CrossRefPubMed

26.

Roehrborn CG, Kaplan SA, Lepor H, Volinn W (2011) Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 14:143–148CrossRefPubMedCentralPubMed

27.

Homma Y, Kawabe K, Takeda M, Yoshida M (2010) Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 76:1446–1450CrossRefPubMed

28.

Hellstrom WJ, Giuliano F, Rosen RC (2009) Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment. Urology 74:15–21CrossRefPubMed

29.

Blanker MH, Bosch JL, Groeneveld FP, Bohnen AM, Prins A, Thomas S, Hop WC (2001) Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 57:763–768CrossRefPubMed

30.

Hutchison A, Farmer R, Chapple C, Berges R, Pientka L, Teillac P, Borkowski A, Dobronski P (2006) Characteristics of patients presenting with LUTS/BPH in six European countries. Eur Urol 50:555–561CrossRefPubMed

Titel: Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH
verfasst von: Nadir I. Osman
Christopher R. Chapple
Teuvo L. Tammela
Andreas Eisenhardt
Matthias Oelke
Publikationsdatum: 01.05.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 5/2015
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-015-1519-2

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Patients and Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study

Prevalence, risk factors, and symptom bother of nocturia: a population-based survey in China

Surgical team composition has a major impact on effectiveness and costs in laparoscopic donor nephrectomy

Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009